Zoliflodacin
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319591

CAS#: 1620458-09-4

Description: Zoliflodacin, also known as AZD0914 and ETX0914, is a new spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor with potent in vitro antibacterial activity against key Gram-positive (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae), fastidious Gram-negative (Haemophilus influenzae and Neisseria gonorrhoeae), atypical (Legionella pneumophila), and anaerobic (Clostridium difficile) bacterial species, including isolates with known resistance to fluoroquinolones. AZD0914 works via inhibition of DNA biosynthesis and accumulation of double-strand cleavages.


Chemical Structure

img
Zoliflodacin
CAS# 1620458-09-4

Theoretical Analysis

MedKoo Cat#: 319591
Name: Zoliflodacin
CAS#: 1620458-09-4
Chemical Formula: C22H22FN5O7
Exact Mass: 487.1503
Molecular Weight: 487.44
Elemental Analysis: C, 54.21; H, 4.55; F, 3.90; N, 14.37; O, 22.98

Price and Availability

Size Price Availability Quantity
100.0mg USD 2850.0 2 Weeks
200.0mg USD 3650.0 2 Weeks
500.0mg USD 4850.0 2 Weeks
Bulk inquiry

Synonym: ETX0914; ETX-0914; ETX 0914; AZD0914; AZD-0914; AZD 0914; Zoliflodacin; CAS#1620458-09-4.

IUPAC/Chemical Name: (2R,4S,4aS)-11-fluoro-2,4-dimethyl-8-((S)-4-methyl-2-oxooxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'H,6H-spiro[isoxazolo[4,5-g][1,4]oxazino[4,3-a]quinoline-5,5'-pyrimidine]-2',4',6'(1'H,3'H)-trione

InChi Key: ZSWMIFNWDQEXDT-ZESJGQACSA-N

InChi Code: InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1

SMILES Code: O=C(NC(C12[C@]([C@H](C)O[C@H](C)C3)([H])N3C4=C(F)C(ON=C5N6C(OC[C@@H]6C)=O)=C5C=C4C2)=O)NC1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 487.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Foerster S, Golparian D, Jacobsson S, Hathaway LJ, Low N, Shafer WM, Althaus CL, Unemo M. Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae. Front Microbiol. 2015 Dec 10;6:1377. doi: 10.3389/fmicb.2015.01377. eCollection 2015. PubMed PMID: 26696986; PubMed Central PMCID: PMC4674575.

2: Su XH, Wang BX, Le WJ, Liu YR, Wan C, Li S, Alm RA, Mueller JP, Rice PA. Multidrug resistant Neisseria gonorrhoeae from Nanjing are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914). Antimicrob Agents Chemother. 2015 Oct 19. pii: AAC.01211-15. [Epub ahead of print] PubMed PMID: 26482313.

3: Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA. In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens. Antimicrob Agents Chemother. 2015 Oct;59(10):6053-63. doi: 10.1128/AAC.01016-15. Epub 2015 Jul 20. PubMed PMID: 26195518; PubMed Central PMCID: PMC4576048.

4: Kern G, Palmer T, Ehmann DE, Shapiro AB, Andrews B, Basarab GS, Doig P, Fan J, Gao N, Mills SD, Mueller J, Sriram S, Thresher J, Walkup GK. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914. J Biol Chem. 2015 Aug 21;290(34):20984-94. doi: 10.1074/jbc.M115.663534. Epub 2015 Jul 6. PubMed PMID: 26149691; PubMed Central PMCID: PMC4543657.

5: Unemo M, Ringlander J, Wiggins C, Fredlund H, Jacobsson S, Cole M. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrob Agents Chemother. 2015 Sep;59(9):5220-5. doi: 10.1128/AAC.00786-15. Epub 2015 Jun 15. PubMed PMID: 26077246; PubMed Central PMCID: PMC4538562.

6: Waites KB, Crabb DM, Duffy LB, Huband MD. In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas. Antimicrob Agents Chemother. 2015;59(6):3627-9. doi: 10.1128/AAC.04945-14. Epub 2015 Mar 30. PubMed PMID: 25824220; PubMed Central PMCID: PMC4432128.

7: Alm RA, Lahiri SD, Kutschke A, Otterson LG, McLaughlin RE, Whiteaker JD, Lewis LA, Su X, Huband MD, Gardner H, Mueller JP. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2015 Mar;59(3):1478-86. doi: 10.1128/AAC.04456-14. Epub 2014 Dec 22. PubMed PMID: 25534723; PubMed Central PMCID: PMC4325766.

8: Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF, Mueller JP. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria. Antimicrob Agents Chemother. 2015 Jan;59(1):467-74. doi: 10.1128/AAC.04124-14. Epub 2014 Nov 10. PubMed PMID: 25385112; PubMed Central PMCID: PMC4291388.

9: Kohlhoff SA, Huband MD, Hammerschlag MR. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014 Dec;58(12):7595-6. doi: 10.1128/AAC.03920-14. Epub 2014 Oct 6. PubMed PMID: 25288086; PubMed Central PMCID: PMC4249501.

10: Jacobsson S, Golparian D, Alm RA, Huband M, Mueller J, Jensen JS, Ohnishi M, Unemo M. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother. 2014 Sep;58(9):5585-8. doi: 10.1128/AAC.03090-14. Epub 2014 Jun 30. PubMed PMID: 24982070; PubMed Central PMCID: PMC4135813.



Additional Information

AZD0914 stabilizes and arrests the cleaved covalent complex of gyrase with double-strand broken DNA under permissive conditions and thus blocks religation of the double-strand cleaved DNA to form fused circular DNA. Whereas this mechanism is similar to that seen with fluoroquinolones, it is mechanistically distinct. AZD0914 exhibited low frequencies of spontaneous resistance in S. aureus, and if mutants were obtained, the mutations mapped to gyrB. Additionally, no cross-resistance was observed for AZD0914 against recent bacterial clinical isolates demonstrating resistance to fluoroquinolones or other drug classes, including macrolides, β-lactams, glycopeptides, and oxazolidinones. AZD0914 was bactericidal in both minimum bactericidal concentration and in vitro time-kill studies. In in vitro checkerboard/synergy testing with 17 comparator antibacterials, only additivity/indifference was observed. The potent in vitro antibacterial activity (including activity against fluoroquinolone-resistant isolates), low frequency of resistance, lack of cross-resistance, and bactericidal activity of AZD0914 support its continued development.